Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31277915 | 0.81 | KDM1A (0.35) | HTR2AHTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL6899425 | 0.80 | NOS3 (0.33) | NOS3NOS1NOS2HTR2AHTR2C | |
| SCHEMBL29991777 | 0.80 | NOS3 (0.33) | NOS3NOS1NOS2HTR2AHTR2C | |
| SCHEMBL13834431 | 0.80 | NOS3 (0.33) | NOS3NOS1NOS2HTR2AHTR2C | |
| SCHEMBL29991327 | 0.80 | NOS3 (0.33) | NOS3NOS1NOS2HTR2AHTR2C | |
| SCHEMBL6920007 | 0.79 | TAAR1 (0.39) | HTR2A | |
| SCHEMBL6900507 | 0.73 | NOTUM (0.32) | NOS3NOS1NOS2NOTUM | |
| SCHEMBL31278211 | 0.70 | KDM1A (0.41) | HTR2CHTR2BKDM1AKDM1B | |
| Hydrochloric Acid SCHEMBL30989938 | 0.69 | KDM1A (0.40) | HTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL29991822 | 0.69 | NOS3 (0.34) | NOS3NOS1NOS2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010100606-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | NOS3 3068/4885NOS1 3478/4885NOS2 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.